FPR 2 agonist - Bristol-Myers Squibb/kyorin pharmaceutical
Alternative Names: FPR-2 Agonist - Bristol-Myers Squibb/kyorin pharmaceuticalLatest Information Update: 28 Oct 2023
At a glance
- Originator Kyorin Pharmaceutical
- Developer Bristol-Myers Squibb; Kyorin Pharmaceutical
- Class Heart failure therapies; Small molecules
- Mechanism of Action Formyl peptide receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Heart-failure in Unknown
- 06 Sep 2020 Phase-I clinical trials in Heart failure (unspecified route)
- 06 Sep 2020 Phase-I clinical trials in Heart failure in Japan (unspecified route) (Bristol-Myers Squibb pipeline, August 2020)